Antiepileptic Drugs Market
Global Antiepileptic Drugs Market Size, Share & Trends Analysis Report by Drug Type (First Generation AEDs- Phenytoin (Dilantin, Phenytek), Carbamazepine (Carbatrol), Oxycarbazepine (Trileptal), Valproate (Depakote & Others) & (Second Generation AEDs- Lamotrigine (Lamictal), Pregabalin (Lyrica), Rufinamide (Banzel/Inovelon), Levetiracetam (Keppra) & Others) Forecast 2022-2028
The global antiepileptic drugs market is anticipated to grow at a significant CAGR of 2.6% during the forecast period. Antiepileptic drug is known as antiseizure drugs. It is used in the treatment of epileptic seizures. Epilepsy is a central neurological disorder that causes abnormal brain function and irregular behaviour, and occasional loss of consciousness. The increasing prevalence of epilepsy is contributing to the growth of the market. For instance, according to World Health Organization (WHO), Epilepsy affects an estimated 5 million individuals worldwide each year. Epilepsy is projected to affect 49 out of every 1,00, 000 people in high-income nations each year. This rate can be as high as 139 per 1,00,000 in low- and middle-income nations.
Antiepileptic drugs, in addition to treating epilepsy and seizures, can also be used to alleviate neuropathic pain. Epileptic seizures have yet to be precisely defined or determined. However, occurrences such as substance abuse disorders, strokes, and brain injuries are the most common causes of epilepsy. Antiepileptic drugs or medicines (AEDs) are provided for the treatment of epilepsy based on the patient's age, the portion of the brain affected, and the type of seizures to be treated. Furthermore, the growing elderly population, changing dietary habits, increased alcohol consumption, and smoking are all contributing to the worldwide anti-epileptic medications market's rise. In the market, anti-epileptic pharmaceuticals are also known as anti-seizure drugs.
Impact of COVID-19 on Global Antiepileptic Drugs Market
The COVID-19 has impacted the global economy due to a slowdown in manufacturing of various industries and long-term effects are projected to impact the industry growth during the forecasted period. It has affected the conduction of clinical trials due to the unavailability of trial site staff and restrictions for traveling. Clinical trials are severely affected by the disruption of existing patients on therapies. For instance, In April 2020, the national center for biotechnology information (NCBI) publishing the report of many clinical trials suspended the trial in order to minimize the risk of contracting COVID-19.
Segmental Outlook
The global antiepileptic drugs market is segmented based on the drug type. Based on the drug type, the market is segmented into first-generation AEDs & second-generation AEDs. Based on the first-generation AEDs, the market is sub-segmented into phenytoin (dilantin, phenytek), carbamazepine (carbatrol), oxycarbazepine (trileptal), valproate (depakote), & others. Based on second-generation AEDs the market is sub-segmented into lamotrigine (lamictal), pregabalin (lyrica), rufinamide (banzel/Inovelon), levetiracetam (keppra), & others. The above-mentioned segments can be customized as per the requirements. Among these, the first-generation AEDs segments the antiepileptic drugs market are majorly dominating the epilepsy market such as carbamazepine, valproate, phenytoin, and oxycarbazepine.
Global Antiepileptic Drugs Market Share by Drug Type, 2021 (%)
The Pregabalin (Lyrica) Segment is Anticipated to Hold a Prominent Share in the Global Antiepileptic Drugs Market
Lyrica segment is anticipated to hold a prominent share in the global antiepileptic drug market. The lyrica is also called the anticonvulsant. It is an affected chemical in the brain chemicals that send pain signals to the nervous system. Additionally, it works by reducing the impulses in the brain that cause fainting. It is also used to treat the pain caused by fibromyalgia, diabetic neuropathy, spinal cord injury, and post-herpetic neuralgia. The increasing prevalence of spinal cord injury and diabetic is contributing to the growth of the segment. For instance, According to the WHO, over 500,000 people suffer from spinal cord injuries each year. Spinal cord injuries have a number of negative physiological and motor consequences.
Regional Outlooks
The global antiepileptic drugs market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America). The market can be analyzed for a particular region or country level as per the requirement. The North America regional antiepileptic drug market is expected to hold a prominent market share due to the presence of several key market players.
Global Antiepileptic Drugs Market Growth, by Region 2022-2028
The North America Region is estimated to Hold the Major Share in the Global Antiepileptic Drugs Market
North America is anticipated to hold a prominent share in the market. It is owing to well-established healthcare infrastructure, advanced technology, and a growing number of product approval by regulatory authorities in the region. In addition, it is launching generic drugs, increasing social awareness and also awareness among the population. The second-generation AEDs are continuously increasing in this region. For instance, in November 2019, SK life Science Inc. received approval from U.S. Food and Drug Administrative for its XCOPRI (cenobamate tablet). It is indicated for the treatment of partial-onset seizures in adults.
Market Players Outlook
The major companies serving the global antiepileptic drugs market include Abbott Laboratories, GlaxoSmithKline plc, Pfizer Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in June 2021, Glenmark Pharma announced the launch of antiepileptic drug rufinamide tablets in the U.S. market. The rufinamide tablet USP in strengths of 200 mg and 400 mg.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global antiepileptic drugs market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Antiepileptic Drugs Market
• Recovery Scenario of Global Antiepileptic Drugs Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Abbott Laboratories
3.1.1.1. Overview
3.1.1.2. Financial Analysis
3.1.1.3. SWOT Analysis
3.1.1.4. Recent Developments
3.1.2. GlaxoSmithKline
3.1.2.1. Overview
3.1.2.2. Financial Analysis
3.1.2.3. SWOT Analysis
3.1.2.4. Recent Developments
3.1.3. Novartis AG
3.1.3.1. Overview
3.1.3.2. Financial Analysis
3.1.3.3. SWOT Analysis
3.1.3.4. Recent Developments
3.1.4. Pfizer Inc.
3.1.4.1. Overview
3.1.4.2. Financial Analysis
3.1.4.3. SWOT Analysis
3.1.4.4. Recent Developments
3.1.5. Sunovion Pharmaceuticals Inc.
3.1.5.1. Overview
3.1.5.2. Financial Analysis
3.1.5.3. SWOT Analysis
3.1.5.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on Key Players
4. Market Segmentation
4.1. Global Antiepileptic Drugs Market by Drug Type
• First Generation AEDs
4.1.1. Phenytoin (Dilantin, Phenytek)
4.1.2. Carbamazepine (Carbatrol)
4.1.3. Oxycarbazepine (Trileptal)
4.1.4. Valproate (Depakote)
4.1.5. Others (Topiramate, Primidone)
• Second Generation AEDs
4.1.1. Lamotrigine (Lamictal)
4.1.2. Pregabalin (Lyrica)
4.1.3. Rufinamide (Banzel/Inovelon)
4.1.4. Levetiracetam (Keppra)
4.1.5. Others (Lacosamide. Perampanel)
5. Regional Analysis
5.1. North America
5.1.1. US
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Abbott Laboratories
6.2. Cephalon, Inc.
6.3. Eisai Co.
6.4. GlaxoSmithKline plc
6.5. GW Pharmaceuticals Inc.
6.6. H. Lundbeck A/S
6.7. Johnson & Johnson
6.8. Novartis AG
6.9. Pfizer Inc.
6.10. Sanofi S.A.
6.11. Sunovion Pharmaceuticals Inc.
6.12. Takeda Pharmaceutical Co. Ltd.
6.13. UCB S.A.
6.14. Valeany Pharmaceuticals International Inc.
1. GLOBAL ANTIEPILEPTIC DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
2. GLOBAL FIRST GENERATION AEDS ANTIEPILEPTIC DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL PHENYTOIN (DIALNTIN, PHENYTEK) ANTIEPILEPTIC DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL CARBAMAZEPINE (CARBATROL) ANTIEPILEPTIC DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL OXYCARBAZEPINE (TRILEPTAL) ANTIEPILEPTIC DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL VALPROATE (DEPAKOTE) ANTIEPILEPTIC DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL OTHERS ANTIEPILEPTIC DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL SECOND GENERATION AEDS ANTIEPILEPTIC DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL LAMOTRIGINE (LAMICTAL) ANTIEPILEPTIC DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL PREGABALIN (LYRICA) ANTIEPILEPTIC DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL RUFINAMIDE (BANZEL/INOVELON) ANTIEPILEPTIC DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
12. GLOBAL LEVETIRACETAM (KEPPRA) ANTIEPILEPTIC DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
13. GLOBAL OTHERS ANTIEPILEPTIC DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
14. GLOBAL ANTIEPILEPTIC DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
15. NORTH AMERICAN ANTIEPILEPTIC DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
16. NORTH AMERICAN ANTIEPILEPTIC DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
17. EUROPEAN ANTIEPILEPTIC DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
18. EUROPEAN ANTIEPILEPTIC DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
19. ASIA-PACIFIC ANTIEPILEPTIC DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
20. ASIA-PACIFIC ANTIEPILEPTIC DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
21. REST OF THE WORLD ANTIEPILEPTIC DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
22. REST OF THE WORLD ANTIEPILEPTIC DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL ANTIEPILEPTIC DRUGS MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL ANTIEPILEPTIC DRUGS MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL ANTIEPILEPTIC DRUGS MARKET, 2022-2028 (%)
4. GLOBAL ANTIEPILEPTIC DRUGS MARKET SHARE BY DRUG TYPE, 2021 VS 2028 (%)
5. GLOBAL FIRST GENERATION AEDS ANTIEPILEPTIC DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL PHENYTOIN (DIALNTIN, PHENYTEK) ANTIEPILEPTIC DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL CARBAMAZEPINE (CARBATROL) ANTIEPILEPTIC DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL OXYCARBAZEPINE (TRILEPTAL) ANTIEPILEPTIC DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL VALPROATE (DEPAKOTE) ANTIEPILEPTIC DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL OTHERS ANTIEPILEPTIC DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11. GLOBAL SECOND GENERATION AEDS ANTIEPILEPTIC DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL LAMOTRIGINE (LAMICTAL) ANTIEPILEPTIC DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL PREGABALIN (LYRICA) ANTIEPILEPTIC DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14. GLOBAL RUFINAMIDE (BANZEL/INOVELON) ANTIEPILEPTIC DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
15. GLOBAL LEVETIRACETAM (KEPPRA) ANTIEPILEPTIC DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
16. GLOBAL OTHERS ANTIEPILEPTIC DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
17. GLOBAL ANTIEPILEPTIC DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
18. US ANTIEPILEPTIC DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
19. CANADA ANTIEPILEPTIC DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
20. UK ANTIEPILEPTIC DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
21. FRANCE ANTIEPILEPTIC DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
22. GERMANY ANTIEPILEPTIC DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
23. ITALY ANTIEPILEPTIC DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
24. SPAIN ANTIEPILEPTIC DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
25. REST OF EUROPE ANTIEPILEPTIC DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
26. INDIA ANTIEPILEPTIC DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
27. CHINA ANTIEPILEPTIC DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
28. JAPAN ANTIEPILEPTIC DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
29. SOUTH KOREA ANTIEPILEPTIC DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
30. REST OF ASIA-PACIFIC ANTIEPILEPTIC DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
31. REST OF THE WORLD ANTIEPILEPTIC DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
